Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA’s “I’m In” Campaign Looks To Connect Minorities To Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

Extension of the Clinical Trial Engagement Network is aimed at increased diversity in clinical trials, which is becoming increasingly important as more drugs are targeted at specific groups.


Related Content

Should US FDA Refuse Approval If Women Under-Represented In Clinical Trials?
Pricing, Pediatrics, Pot: 21st Century Cures Amendments
Clinical Trial Diversity: ‘How Much More Evidence Do We Need To Move Forward?’
FDA Working To Make Subgroups Stand Out
FDA Working To Make Subgroups Stand Out
Lung-MAP Patient Screening Should Translate To Cost-Savings
PhRMA To Assist Pay-For-Locate Trial Enrollment Tool To Boost Study Diversity
BIO Looking For Clinical Trial Reform Priorities
Diabetes Drug Developers Urged To Study Higher Risk Patients By FDA Panel
Drug-Induced Liver Injury Workshop Offers More Questions Than Answers





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts